Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Assets (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Assets for 16 consecutive years, with $166.1 million as the latest value for Q4 2025.

  • Quarterly Assets rose 32.48% to $166.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $166.1 million through Dec 2025, up 32.48% year-over-year, with the annual reading at $166.1 million for FY2025, 32.48% up from the prior year.
  • Assets for Q4 2025 was $166.1 million at Gyre Therapeutics, up from $159.4 million in the prior quarter.
  • The five-year high for Assets was $166.1 million in Q4 2025, with the low at $10.0 million in Q3 2023.
  • Average Assets over 5 years is $92.7 million, with a median of $109.2 million recorded in 2021.
  • The sharpest move saw Assets tumbled 85.13% in 2023, then soared 1156.92% in 2024.
  • Over 5 years, Assets stood at $55.7 million in 2021, then surged by 52.26% to $84.8 million in 2022, then soared by 37.5% to $116.5 million in 2023, then grew by 7.61% to $125.4 million in 2024, then surged by 32.48% to $166.1 million in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $166.1 million, $159.4 million, and $152.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.